Spots Global Cancer Trial Database for alcl
Every month we try and update this database with for alcl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Safety Study of SGN-35T in Adults With Advanced Cancers | NCT06120504 | Lymphoma, T-Cel... Hodgkin Disease Lymphoma, T-Cel... Lymphoma, Large... Lymphoma, Large... Lymphoma, Non-H... | SGN-35T | 18 Years - | Seagen Inc. | |
| Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) | NCT01657331 | Hodgkin Lymphom... Anaplastic Larg... | Brentuximab Ved... Bendamustine Neulasta | 18 Years - | Columbia University | |
| Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy. | NCT02464228 | Relapsed or Ref... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) | NCT02169505 | Lymphoma | Brentuximab Ved... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas | NCT00082017 | Lymphoma, Large... Lymphoma, T-Cel... | UCN-01 (7-hydro... | 12 Years - | National Institutes of Health Clinical Center (CC) | |
| Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas | NCT02223208 | Peripheral T-ce... PTCL-NOS Angioimmunoblas... ALK- Anaplastic... Nodal Periphera... | Ro-CHOEP-21 (PH... Ro-CHOEP-21 (PH... | 18 Years - 65 Years | Fondazione Italiana Linfomi - ETS | |
| MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma | NCT00298467 | Lymphoma, Large... | MDX-060 | 12 Years - | Bristol-Myers Squibb | |
| Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies | NCT02780011 | CD30-positive L... CD30-positive S... | Brentuximab Ved... Alsertib | 18 Years - | The Methodist Hospital Research Institute | |
| SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | NCT01352520 | CD-30 Positive ... Lymphoma, Prima... Lymphomatoid Pa... Mycosis Fungoid... Skin Lymphoma Cutaneous Lymph... Lymphoma Hematologic Dis... | SGN-35 | 18 Years - | M.D. Anderson Cancer Center | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK + | NCT02902874 | ALCL | Blood sample | - | Gustave Roussy, Cancer Campus, Grand Paris | |
| UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas | NCT00082017 | Lymphoma, Large... Lymphoma, T-Cel... | UCN-01 (7-hydro... | 12 Years - | National Institutes of Health Clinical Center (CC) | |
| MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma | NCT00298467 | Lymphoma, Large... | MDX-060 | 12 Years - | Bristol-Myers Squibb | |
| Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy. | NCT02464228 | Relapsed or Ref... | Tipifarnib | 18 Years - | Kura Oncology, Inc. | |
| A Safety Study of SGN-35T in Adults With Advanced Cancers | NCT06120504 | Lymphoma, T-Cel... Hodgkin Disease Lymphoma, T-Cel... Lymphoma, Large... Lymphoma, Large... Lymphoma, Non-H... | SGN-35T | 18 Years - | Seagen Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
